Delcath lifts 2026 revenue guidance on HEPZATO KIT momentum
Aug 6, 2026, 8:03 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The upward revision of 2026 revenue guidance to 104–108M, strong HEPZATO KIT contribution (27.1M), and 31 active centers imply improved revenue visibility and potential margin/EBITDA progression. History shows that material guidance raises in healthcare tech/biotech equipment providers often drive multiple expansion or at least short-term upside as investors re-price growth prospects. Positive cash flow and no debt further support optionality for expansion and R&D for Phase 2 trials.
AI summary
What happened, with direct paths to the underlying reporting
Delcath reported Q2 2026 revenue of $29.1M, led by HEPZATO KIT at $27.1M and CHEMOSAT at $2.0M. The company raised 2026 revenue guidance to $104–$108M and maintains positive EBITDA, supported by 31 active centers and roughly 30% YoY growth in HEPZATO volume. The data underscore a potential multi-indication liver-directed therapy platform with expanding physician adoption.
2026 revenue guidance raised to $104–$108M; 28% HEPZATO KIT growth.
31 active centers; ~30% YoY growth in HEPZATO volume.
First patient dosed in HER2-negative metastatic breast cancer Phase 2.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
